IDEAYA Biosciences Soars on Cancer Drug Study Results

By
Bill McColl
Bill McColl
Full Bio

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of the most notable news stories of the time.

Learn about our editorial policies
Published July 08, 2024
A pharmaceutical technical assistant and a pharmacist produce cancer drugs

Rolf Vennenbernd / picture alliance via Getty Images

Key Takeaways

  • IDEAYA Biosciences reported positive results from a Phase 2 trial of its experimental drug to treat certain bladder and small-cell lung cancers on Monday, and shares soared in intraday trading.
  • The once-a-day tablet IDE397 helped patients with MTAP-deletion solid cancers.
  • The company noted there are no Food and Drug Administration (FDA)-approved drugs for those who have MTAP-deletion solid tumors.

Shares of IDEAYA Biosciences (IDYA) took off in intraday trading Monday after the biotech announced positive results in a mid-stage study of its treatment for certain bladder and small-cell lung cancers.

The company said its Phase 2 trial of IDE397 worked for patients with methylthioadenosine phosphorylase (MTAP)-deletion solid cancers. IDEAYA reported a 94% disease control rate, and 78% of patients had tumor shrinkage while taking the 30mg, once-a-day tablet.

The company noted that there currently are no Food and Drug Administration (FDA)-approved treatments for MTAP-deletion solid tumors. It estimates that some 48,000 people in the U.S. suffer from MTAP-deletion bladder and small-cell lung cancers.  

IDEAYA 'Highly Encouraged' by Results

Chief Medical Officer Dr. Darrin Beaupre explained that IDEAYA is “highly encouraged” by the results, and that IDE397 “has the potential to enable longer duration dosing as well as combinations.”  

The report lifted shares of IDEAYA Biosciences up more than 13% to $38.86 as of 12:05 p.m. ET and into positive territory for the year.

Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.

  1. IDEAYA Biosciences. "IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer."

Take the Next Step to Invest
×
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.